Efficacy of Dulaglutide (DU) as First Injectable Option for Patients with Type 2 Diabetes (T2D): A Post Hoc Pooled Analysis

被引：0
|
作者：
Patel, Hiren
Munir, Kashif M.
Sutherland, Sindee S.
Konig, Manige
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-2303-PUB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2303-PUB
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis
    Patel, Hiren
    Munir, Kashif
    Sutherland, Sindee
    Karanikas, Chrisanthi A.
    Konig, Manige
    DIABETES THERAPY, 2019, 10 (06) : 2321 - 2330
  • [2] Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis
    Hiren Patel
    Kashif Munir
    Sindee Sutherland
    Chrisanthi A. Karanikas
    Manige Konig
    Diabetes Therapy, 2019, 10 : 2321 - 2330
  • [3] Higher Doses of Dulaglutide Induce Weight Loss in Patients with Type 2 Diabetes (T2D) Regardless of Baseline BMI: Post-hoc Analysis of AWARD-11
    Bonora, Enzo
    Frias, Juan P.
    Malik, Raleigh
    Kwan, Anita
    Raha, Sohini
    Bethel, Angelyn
    Cox, David
    DIABETES, 2021, 70
  • [4] Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis
    Miao Yu
    Guo Yue Yuan
    Bin Zhang
    Hai Ya Wu
    Xiao Feng Lv
    Diabetes Therapy, 2020, 11 : 1147 - 1159
  • [5] Reduction of A1c with Dulaglutide in Type 2 Diabetes (T2D) Patients Positive or Negative for GAD Antibodies (GADA): A Post-hoc Analysis of AWARD-2,-4, and-5
    Pozzilli, Paolo
    Leslie, Richard D.
    Peters, Anne
    Buzzetti, Raffaella
    Milicevic, Zvonko
    Pavo, Imre
    Lebrec, Jeremie
    Martin, Sherry
    Schloot, Nanette
    DIABETES, 2017, 66 : A287 - A287
  • [6] Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis
    Yu, Miao
    Yuan, Guo Yue
    Zhang, Bin
    Wu, Hai Ya
    Lv, Xiao Feng
    DIABETES THERAPY, 2020, 11 (05) : 1147 - 1159
  • [7] Gene Expression and Metformin Efficacy in Type 2 Diabetes (T2D)
    Prudente, Sabrina
    Masotti, Andrea
    Copetti, Massimiliano
    Caporarello, Nunzia
    Proto, Vittoria
    Da Sacco, Letizia
    Morini, Eleonora
    Mercuri, Luana
    Bailetti, Diego
    Palena, Antonio
    Baratta, Roberto
    De Cosmo, Salvatore
    Pellegrini, Fabio
    Ludovico, Ornella
    Frittitta, Lucia
    Trischitta, Vincenzo
    DIABETES, 2013, 62 : A430 - A430
  • [8] Efficacy and Cardiovascular (CV) Safety of Linagliptin as Add-on to Insulin in Type 2 Diabetes (T2D)-A Pooled Comprehensive Posthoc Analysis
    Zinman, Bernard
    Ahren, Bo
    Neubacher, Dietmar
    Patel, Sanjay
    Johansen, Odd Erik
    Woerle, Hans J.
    DIABETES, 2014, 63 : A274 - A274
  • [9] Adherence and Persistence for Dulaglutide (DU) vs. Basal Insulin (BI) in Injection-Naive Patients with Type 2 Diabetes (T2D): The DISPELTM Study
    Mody, Reema
    Huang, Qing
    Yu, Maria
    Wang, Liya
    Zhang, Xian
    Grabner, Michael
    Patel, Hiren
    DIABETES, 2019, 68
  • [10] Changes in lipid concentrations in patients with type 2 diabetes on once-weekly dulaglutide 1.5 mg: post hoc pooled analysis of the AWARD trials
    Pavo, I.
    Garcia-Perez, L. -E.
    Tao, Y.
    Thieu, V. T.
    Sattar, N. A.
    DIABETOLOGIA, 2017, 60 : S258 - S258
12345